World journal of clinical oncology最新文献_第10页

Novel approach to risk stratification: Integrating waist-hip ratio for predicting advanced colorectal neoplasia. 风险分层的新方法：综合腰臀比预测晚期结直肠肿瘤。

IF 3.2

World journal of clinical oncology Pub Date : 2025-10-24 DOI: 10.5306/wjco.v16.i10.109843

Arvind Mukundan, Devansh Gupta, Riya Karmakar, Hsiang-Chen Wang

{"title":"Novel approach to risk stratification: Integrating waist-hip ratio for predicting advanced colorectal neoplasia.","authors":"Arvind Mukundan, Devansh Gupta, Riya Karmakar, Hsiang-Chen Wang","doi":"10.5306/wjco.v16.i10.109843","DOIUrl":"10.5306/wjco.v16.i10.109843","url":null,"abstract":"The urgent necessity for enhanced risk stratification to improve the efficiency of colonoscopy screening is underscored by the fact that colorectal cancer (CRC) continues to be a primary cause of global cancer mortality. Conventional models mostly rely on generalized obesity markers including body mass index (BMI), which does not effectively represent oncogenic risk linked with abdominal obesity. Liu et al undertook a large-scale case-control study comprising 6484 first-time colonoscopy patients at a prominent Chinese hospital between 2020 and 2023 to overcome this restriction. Age, male sex, smoking status, and raised waist-hip ratio (WHR) were found by multivariate logistic regression as independent predictors of advanced colorectal neoplasia (ACN). In a validation cohort of 1891 individuals, a new 7-point risk scoring model was created and stratified into low- (5.0%) ACN prevalence, moderate- (10.3%) and high-risk (17.6%). With C-statistic = 0.66 the model showed better discriminating ability than the Asia-Pacific Colorectal Screening (APCS) score (C-statistic = 0.63) and the BMI-modified APCS model. These results fit newly published data showing central obesity as a major carcinogenic driver via pro-inflammatory visceral adipokine channels. With the use of WHR, patient risk classification is greatly improved, providing a practical tool to make the most of screening resources in the face of rising CRC incidence rates. Finally, multi-ethnic validation is necessary for the WHR-based scoring model to be considered for integration into global CRC preventive frameworks, since it improves the accuracy of ACN risk prediction.","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 10","pages":"109843"},"PeriodicalIF":3.2,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12576516/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145432454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Surgeons' opinions about enhanced recovery after surgery for retroperitoneal sarcoma: A survey. 外科医生对提高腹膜后肉瘤术后恢复的看法：一项调查。

IF 3.2

World journal of clinical oncology Pub Date : 2025-10-24 DOI: 10.5306/wjco.v16.i10.108419

Luca Improta, Chiara Maura Ciniselli, Paolo Verderio, Sandro Pasquali, Marco Fiore, Sergio Valeri

{"title":"Surgeons' opinions about enhanced recovery after surgery for retroperitoneal sarcoma: A survey.","authors":"Luca Improta, Chiara Maura Ciniselli, Paolo Verderio, Sandro Pasquali, Marco Fiore, Sergio Valeri","doi":"10.5306/wjco.v16.i10.108419","DOIUrl":"10.5306/wjco.v16.i10.108419","url":null,"abstract":"Background: Enhanced recovery after surgery (ERAS) programs provide recommendations for an optimized management of patients undergoing surgery. An ERAS program tailored on surgery for retroperitoneal sarcomas (RPS) may improve patient outcomes and it has still not been established.Aim: To determine how an ERAS program tailored to RPS surgery can be agreed upon, structured, and implemented.Methods: Twenty-five candidate items from existing ERAS programs, potentially relevant for RPS surgery, were identified via literature review and expert input. These were included in a questionnaire refined through cognitive interviews and pilot testing. Expert sarcoma surgeons rated each item's relevance and feasibility on a 6-point scale. The survey was recirculated after one year. Intra-observer reproducibility, inter-observer concordance, and agreement with the modal value of the most experienced participants were analyzed.Results: Thirteen sarcoma surgeons from 6 centers participated in the survey. Although surgeons agreed on several items, their overall concordance was low. After recirculating the survey, the intra-observer reproducibility was low. Interestingly, the median concordance with the reference increased for relevance and decreased for feasibility.Conclusion: Despite interest in ERAS for RPS, surgeon concordance on item relevance and feasibility remains low, underscoring the need for collaborative efforts toward a standardized, consensus-based protocol.","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 10","pages":"108419"},"PeriodicalIF":3.2,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12576518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145431553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Charged multivesicular body protein 7 as a prognostic biomarker in colorectal cancer metastasis. 带电多泡体蛋白7作为结直肠癌转移的预后生物标志物。

IF 3.2

World journal of clinical oncology Pub Date : 2025-10-24 DOI: 10.5306/wjco.v16.i10.110056

Mesut Tez

引用次数: 0

Overcoming chemoresistance in non-small cell lung cancer: Insights into the influence of inflammatory factors on treatment response. 克服非小细胞肺癌的化疗耐药：炎症因子对治疗反应的影响

IF 3.2

World journal of clinical oncology Pub Date : 2025-10-24 DOI: 10.5306/wjco.v16.i10.112097

Yue Dai, Ya-Yun Liu, Nian Cao, Xiu-Wen Tian, Juan Feng, Zhen-Zhen Hu, Jian-Qiang Xu

{"title":"Overcoming chemoresistance in non-small cell lung cancer: Insights into the influence of inflammatory factors on treatment response.","authors":"Yue Dai, Ya-Yun Liu, Nian Cao, Xiu-Wen Tian, Juan Feng, Zhen-Zhen Hu, Jian-Qiang Xu","doi":"10.5306/wjco.v16.i10.112097","DOIUrl":"10.5306/wjco.v16.i10.112097","url":null,"abstract":"Background: Non-small cell lung cancer (NSCLC) is frequently characterized by poor response to cisplatin (DDP)-based chemotherapy, with increasing evidence suggesting that inflammatory cytokines in the tumor microenvironment contribute to chemoresistance.Aim: To investigate the role of inflammatory cytokines in DDP resistance and to effect of IL-6 inhibition on chemosensitivity in NSCLC.Methods: Twenty NSCLC patients were grouped into DDP-sensitive or DDP-resistant cohorts based on their clinical response. Cytokine levels in tumor tissues and NSCLC cell lines, including DDP-resistant A549/DDP and SK-MES-1/DDP, were quantified using enzyme-linked immunosorbent assay. To verify the effects of interleukin (IL)-6 on DDP resistance, NSCLC and resistant cells were treated with IL-6 inhibitors tocilizumab (TCZ), followed by DDP treatment. Cell viability, apoptosis, migration and invasion were detected via cell counting kit-8, flow cytometry, scratch assay, and transwell, respectively.Results: IL-6, IL-8, and tumor necrosis factor-α levels were significantly elevated in DDP-resistance tissues and cell models compared to sensitive controls (P < 0.05). TCZ treatment significantly reduced the half-maximal inhibitory concentration of DDP in resistant cells, induced apoptosis, and hindered migration and invasion (P < 0.05). IL-6 and IL-8 were identified as key cytokines associated with DDP resistance.Conclusion: These findings demonstrated that IL-6 and related cytokines contribute to DDP resistance in NSCLC. IL-6 inhibition restores chemosensitivity and may serve as a promising therapeutic strategy in resistant NSCLC.","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 10","pages":"112097"},"PeriodicalIF":3.2,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12576530/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145432499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inflammatory biomarkers in the pathogenesis of pancreatic cancer: A literature review. 胰腺癌发病机制中的炎症生物标志物：文献综述。

IF 3.2

World journal of clinical oncology Pub Date : 2025-10-24 DOI: 10.5306/wjco.v16.i10.109385

Ayesha Aslam, Hafsa Hamid, Eman Fatima, Sumaira Pervaiz, Mehnaz Arif, Huda Irshad, Amina Shafqat, Sara Khan, Huma Khurshid, Saira Rafaqat

引用次数: 0

Global gene expression landscape of gallbladder cancer and advances in targeted therapeutic strategies. 胆囊癌的全球基因表达格局及靶向治疗策略进展。

IF 3.2

World journal of clinical oncology Pub Date : 2025-10-24 DOI: 10.5306/wjco.v16.i10.111028

Sounetra Choudhury, Arunima Maiti, Arnab Bandopadhyay, Anusri Tripathi, Nilabja Sikdar

{"title":"Global gene expression landscape of gallbladder cancer and advances in targeted therapeutic strategies.","authors":"Sounetra Choudhury, Arunima Maiti, Arnab Bandopadhyay, Anusri Tripathi, Nilabja Sikdar","doi":"10.5306/wjco.v16.i10.111028","DOIUrl":"10.5306/wjco.v16.i10.111028","url":null,"abstract":"Gallbladder cancer (GBC) is a lethal biliary tract malignancy, which is infrequent in most developed countries, but common in many developing countries in specific geographical regions of the world. Non-specific symptoms leading to late diagnosis is one of the primary factors contributing to poor prognosis in GBC. An understanding of the complex relationship between molecular genetics and epidemiological variances in the incidence rates of GBC is thus of utmost importance. Present review summarizes recent updates on population-specific dysregulated genetic expressions in the genesis of GBC, highlighting the pattern of ethno-geographic variations and on advances in targeted therapies conducted till date; points out the lacunae that deserve further attention and suggest possible new directions for future clinical trials in GBC. The review calls for the need of genetic screening of each GBC patients and for more extensive clinical trials on targeted therapies to move towards the goal of personalized medicine, bringing about more favourable survival outcomes.","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 10","pages":"111028"},"PeriodicalIF":3.2,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12576526/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145432327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sidedness matters: Colon cancer outcomes in low-resource settings. 侧边性问题：低资源环境下结肠癌的预后。

IF 3.2

World journal of clinical oncology Pub Date : 2025-10-24 DOI: 10.5306/wjco.v16.i10.108937

Jaime González-Montero, Guillermo Valenzuela, Carlos I Rojas, Mauricio Burotto

{"title":"Sidedness matters: Colon cancer outcomes in low-resource settings.","authors":"Jaime González-Montero, Guillermo Valenzuela, Carlos I Rojas, Mauricio Burotto","doi":"10.5306/wjco.v16.i10.108937","DOIUrl":"10.5306/wjco.v16.i10.108937","url":null,"abstract":"Colon cancer (CC) laterality (right vs left) is recognized as a key determinant of clinical outcomes and treatment decisions in metastatic CC. Right-sided CC (RCC) often presents in older individuals and is associated with higher rates of Kirsten rat sarcoma viral oncogene homolog and v-raf murine sarcoma viral oncogene homolog B1 mutations and deficient mismatch repair, leading to microsatellite instability-high status. Left-sided CC typically presents in younger individuals, demonstrates a more favorable prognosis, and is often Kirsten rat sarcoma viral oncogene homolog/neuroblastoma RAS viral oncogene homolog/v-raf murine sarcoma viral oncogene homolog B1 wild-type, making it more responsive to anti-epidermal growth factor receptor therapy. RCC typically responds poorly to anti-epidermal growth factor receptor agents; however, it may benefit from triplet chemotherapy (5-fluorouracil + leucovorin + oxaliplatin + irinotecan) with or without anti-angiogenic agents. Comprehensive molecular profiling remains challenging in low-resource settings due to limited access to advanced diagnostic tools. This review explores key epidemiological and molecular differences between RCC and left-sided CC. In the absence of complete genomic data, tumor sidedness can be a helpful guide for making treatment decisions. Here, we propose a practical algorithm that integrates basic immunohistochemistry to assess a tumor's mismatch repair status and laterality, potentially facilitating therapy selection in resource-constrained environments. Recognizing laterality-specific trends in prognosis and treatment response can improve personalized care and outcomes for patients with CC in these environments, highlighting the essential role of cost-effective biomarker strategies.","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 10","pages":"108937"},"PeriodicalIF":3.2,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12576533/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145432486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advances of circular RNAs in gastrointestinal cancer. 环状rna在胃肠道肿瘤中的研究进展。

IF 3.2

World journal of clinical oncology Pub Date : 2025-10-24 DOI: 10.5306/wjco.v16.i10.111115

Long-Fei Xie, Sheng-Yan Liu, Xiao-Wei Dang

引用次数: 0

Circulating tumor DNA in biliary tract cancers: A review of current applications. 循环肿瘤DNA在胆道肿瘤中的应用综述。

IF 3.2

World journal of clinical oncology Pub Date : 2025-10-24 DOI: 10.5306/wjco.v16.i10.107875

Maria Fernanda Teixeira, Mitesh Borad, Pedro Luiz Serrano Uson Junior

{"title":"Circulating tumor DNA in biliary tract cancers: A review of current applications.","authors":"Maria Fernanda Teixeira, Mitesh Borad, Pedro Luiz Serrano Uson Junior","doi":"10.5306/wjco.v16.i10.107875","DOIUrl":"10.5306/wjco.v16.i10.107875","url":null,"abstract":"Molecular profiling of biliary tract cancers (BTCs) has paved the way for a broader range of therapeutic options, leading to improved survival outcomes. Given the challenges of tissue evaluation in BTCs, circulating tumor DNA (ctDNA) has emerged as a promising non-invasive biomarker for genomic profiling. Bile has been proven to be a reliable ctDNA source, demonstrating higher concordance with tumor tissue than plasma. More importantly, ctDNA provides valuable insights into both clonal evolution and treatment response, including the detection of resistance mechanisms and mutation clearance, which are often associated with disease control. Although its role in recurrence monitoring remains investigational, early studies suggest that ctDNA detection may precede radiological recurrences. This review examines recent advancements in ctDNA analysis for patients with BTC, highlighting key developments, current clinical implications, and ongoing challenges. Large-scale prospective studies are needed to validate the clinical utility of ctDNA and to support its integration into BTC management.","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 10","pages":"107875"},"PeriodicalIF":3.2,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12576521/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145432341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radiotherapy treatment time delay evidence, part I: Update on cervical, anal, prostate, and head and neck cancers. 放疗治疗时间延迟证据，第一部分：宫颈癌、肛门癌、前列腺癌和头颈癌的最新进展。

IF 3.2

World journal of clinical oncology Pub Date : 2025-10-24 DOI: 10.5306/wjco.v16.i10.109247

Jose Antonio González Ferreira, Castalia Fernandez, Daniela Gonsalves, Imanol Paguey, Felipe Couñago

{"title":"Radiotherapy treatment time delay evidence, part I: Update on cervical, anal, prostate, and head and neck cancers.","authors":"Jose Antonio González Ferreira, Castalia Fernandez, Daniela Gonsalves, Imanol Paguey, Felipe Couñago","doi":"10.5306/wjco.v16.i10.109247","DOIUrl":"10.5306/wjco.v16.i10.109247","url":null,"abstract":"Treatment delays during radiotherapy for head and neck cancer (HNC) are a well-established factor negatively affecting clinical outcomes, with similar trends observed in other cancers. In this first part of a two-part review, we assessed the impact of overall treatment time (OTT) prolongation on locoregional control (LRC) and survival (SV) in cervical cancer (CC), prostate cancer (PC), and anal cancer (AC), while updating evidence for HNC. A comprehensive literature search was performed in evidence-based databases, including MEDLINE, identifying studies evaluating the relationship between OTT prolongation and outcomes. Particular attention was paid to the strength of evidence, distinguishing univariate analysis from multivariate analysis (MV-An). For CC, 37 articles were identified, with 88.8% reporting a detrimental impact on LRC and/or SV, mostly supported by MV-An. In AC, 15 studies were found, with 33.3% showing negative impacts, although with weaker evidence. For PC, 12 articles were reviewed, with 66.6% demonstrating detrimental effects mainly on LRC or biochemical control, and occasional associations with cancer-specific SV. Recent studies in HNC reinforced prior findings. When available, radiobiological parameters and practical recommendations are provided. In conclusion, strong evidence confirms that prolonged OTT worsens outcomes in HNC and CC, with less consistent but relevant effects in PC and AC.","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 10","pages":"109247"},"PeriodicalIF":3.2,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12576527/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145432447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0